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ABSTRACT 
Objective: The objective of the study was to determine the effect of consumption of black cumin seed oil (BCSO) on platelet count, clotting time 
(CT), and bleeding time (BT) in healthy-smoker volunteers (HSV). 
Methods: Participants were 39 healthy male smokers aged 18-66 y. Participants were divided into four groups randomly. The treatment group 
received BCSO for thirties days in 3x1, 3x2, and 3x3 capsules/day doses. The placebo group received a placebo preparation. We measured CT, BT, 
and platelet count on day 31. An analysis of the mean difference between CT, BT, and platelet counts was performed using one-way ANOVA. 
Result: The results showed that the CT, BT, and platelet counts in all groups were within normal. Consumption of BCSO for 30 d did not affect CT, 
BT, and platelet counts of HSV. The results of the analysis of the mean difference test between groups of CT, BT, and platelet counts indicated that 
there was no difference with p>0.05. 
Conclusion: We concluded that the 30-day BCSO consumption did not affect the CT, BT, and platelet count values in HSV. 
Keywords: Black cumin seed oil, Hemostasis, Healthy-smoker volunteer, Open-label clinical trial 
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INTRODUCTION  
Smoking is one of the public health problems in Indonesia [1]. 
Cigarettes are addictive, toxic, carcinogenic, and 
immunosuppressant [2, 3]. Cigarette exposure is associated with an 
increased incidence of hypertension, diabetes mellitus, cardiac 
ischemia, stroke, and kidney failure [4-7]. The addictive nature of 
cigarettes comes from the nicotine they contain. After cigarette 
smoke is inhaled, nicotine will reach the brain [8, 9]. Smoking is one 
of the factors that can cause an increase in plasma homocysteine 
levels and radical reactive in the body [10, 11]. Homocysteine affects 
several factors involved in the blood clotting cascade, such as 
decreasing anti-thrombin activity, accelerating thrombus formation, 
and increasing platelet aggregation [12]. Homocysteine also 
suppresses natural thrombolysis by reducing tissue plasminogen 
activator [13]. Homocysteine causes damage to the endothelium 
[14]. This damage causes a decrease in the production of 
prostacyclin, which can cause thrombus to form in the vascular 
system, resulting in thrombosis [11, 15]. Clotting Time (CT) and 
Bleeding time (BT) are routine examinations to determine the 
intrinsic and extrinsic coagulation pathways. Platelets are blood cells 
that are responsible react to bleeding from blood vessel injury by 
clumping, thereby initiating a blood clot. Platelets in a resting state 
circulate in the bloodstream. Platelets will undergo rapid 
deformation at the injury site in the event of a vascular injury, where 
they roll over, stick together, and collect to stop bleeding with 
thrombus formation [16, 17]. Smoking habits are associated with 
coagulation factors malfunctions [18]. Smoking habits are also 
thought to be related to changes in CT and BT values. 
Black cumin (Nigella sativa L.) is one of the Nigella genus [19]. 
Nigella sativa is useful for increasing stamina and body defense [20], 
antioxidants and anti-aging [21], anti-infection [22] and prevention 
of degenerative diseases (cancer, diabetes mellitus, stroke, 
hypertension) [23]. One of the most important active compounds 
contained in black cumin is thymoquinone [24]. Thymoquinone is 
anti-oxidative [25], immunomodulatory, chemopreventive, and anti-
inflammatory [26, 27]. Antioxidants can inhibit oxidative stress and 
reduce the potential for damage to cell structure and function [28]. 
Tobacco smoking causes oxidative stress [29]. Oxidative stress is a 
condition in which the formation of reactive oxygen species (ROS) 
and long-term antioxidant defense systems is not balanced in the 
body [30, 31]. Oxidative stress can cause various disorders such as 
cardiovascular disease, diabetes, rheumatoid arthritis, cancer, and 
neurodegenerative disorders [32]. Antioxidants are responsible for 
the body's mechanisms for fighting disease pathologies related to 
the free radical attack [33]. Thymoquinone and antioxidants agents 
are believed to play an essential role in the body's defense system 
against radical reactive and maintain overall body health [34]. 
Consumption of BCSO is thought to inhibit the increase in platelet 
counts and normalize CT and BT values in smokers. The purpose of 
this study was to determine the effect of administration of BCSO for 
30 d on the platelet count, clotting time, and bleeding time in 
healthy-smokers volunteers. 
MATERIALS AND METHODS 
Types and research design 
In this study, the experimental design used was Open-Label 
Randomized Controlled Trial. Three BCSO dosage ratings were 
given, namely 3x1; 3x2; and 3x3 capsules/day. We carried out the 
research protocol following the Declaration of Helsinki, where the 
research protocol had been reviewed and had obtained ethics 
worthy statements from the UAD research ethics committee. 
Materials, tools, and subjects 
The research materials included BCSO capsules containing 
standardized BCSO and placebo preparations. The placebo and BCSO 
capsules are prepared by the traditional medicine industry certified 
by the National Agency of Drug and Food Control. The equipment 
needed in the research includes a weight scale, thermometer, 
tensimeter, test tube, stopwatch, and hemato analyzer. 
Inclusion criteria were healthy volunteers and active smokers. Men 
aged>18 y and willing to become participants (as evidenced by a 
willingness to fill and sign the informed consent). Exclusion criteria 
were volunteer smokers who suffered from chronic diseases, missed 
medication schedules, and used supplements other than BCSO. 
Participants who experienced an incidence of side effects to be 
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excluded from the study. Following phase 1 research guidelines, this 
study involved 39 participants. 
Participant recruitment for research procedures 
Prospective subjects who meet the inclusion criteria are asked to 
participate in the study by signing the informed consent after 
explaining the objectives, benefits, and research procedures and 
consequences and compensation as participants. Prospective 
participants who have signed the informed consent are then 
subjected to a physical examination to determine the clinical 
condition and physical health status by the Puskesmas doctor. 
The assignment in the experimental group 
Placement of participants into the test group was done randomly 
using the manual method (coins). Participants were divided into 
four groups. The pharmacist stores the random numbers were 
resulting from the randomization process. Group I, namely the 
control/placebo group, subjects received a soft capsule without 
BCSO. Group II, III, and IV, the subjects received BCSO capsules at a 
dose of 3x1, 3x2, and 3x3/day. BCSO is a soft capsule containing 
BCSO, where one capsule contains±450 mg of BCSO (excluding 
capsule shell). 
Implementation of the provision of BCSO and monitoring 
Both placebo and BCSO are given for 30 d, which are consumed 
regularly. Monitoring the condition of the participants is carried out 
twice a week through direct interviews with residents' houses. 
Monitoring the participant's situation includes clinical conditions 
(blood pressure, respiration, temperature, and pulse), complaints, 
and effects that arise after administration, including side effects and 
ascertaining the amount of medication remaining and 
supplementing the case report form (CRF). 
Data retrieval 
On the 31st day, participants/volunteers have collected again for 
blood sampling for complete blood counts, clinical examination, and 
education and dissemination on the need for a healthy lifestyle. The 
researcher presented the first laboratory examination (pre-
treatment), providing clinical interpretation and recommendations 
for follow-up. We sent the blood to Nur Hidayah Hospital for platelet 
counts using a hemato-analyzer. We determined clotting time using 
the Lee-white method and bleeding time using the Ivy method. 
Data analysis 
Participant characteristics are presented descriptively in the form of 
a percentage. We determined the difference in the proportion of 
demographic and smoking habits characteristics between groups 
using the chi-square. We performed a mean difference test between 
groups for the mean of CT, BT, and platelet count using the one-way 
ANOVA, with a 95% confidence level. 
RESULTS AND DISCUSSION 
Characteristics of the subject 
Based on research conducted on men over 18 y old at PHC Jetis 1 Bantul 
Yogyakarta (PJ1BY), where BCSO effects on clotting time and bleeding 
time in smokers. This research was conducted by filling out the 
nutritional recall form. Respondents have signed informed consent 
before recruited, and the ethics commission has approved all protocols. 
It is known that the Subjects who consumed the BCSO were in the 
age range<60 y, as many as 39 volunteers. Table 1 showed the 
demographic characteristics of the Subject. Most of the participants 
have a junior high school education, with a livelihood as masons and 
carpenters. Most of the participants smoked less than ten 
cigarettes/day and had lasted 10-30 y. 
 
Table I: Distribution of characteristics of healthy-smoker volunteers (HSV) who consume BCSO in the working area of PJ1BY in 
september-october 2019 
Characteristic Placebo BCSO 3X1 BCSO 3X2 BCSO 3X3 Total Significance (2-sided) 
1. Age       













2. Education       
Elementary 0 0 4 2 6 0.25 
Yunior Hight school 2 0 2 1 5 













3. Job        
Labor 5 2 6 5 18 0.37 
Teacher 0 1 0 0 1 
Students a 0 0 0 1 1 
Retired  0 1 0 0 1 













4. Smoking habit type       













5. Number of stick/day       













6. Duration of smoking (year)       
<10 y 2 4 2 2 10 0.53 
10-30 y 7 4 7 5 23 
>30 y 0 1 3 2 6 
Total 9 9 12 9 39  
 
The clinical conditions of participants before administering BCSO 
are presented in table 2. Based on the data in table 2, it is known that 
the participants' blood pressure, temperature, pulse, BMI, urea, 
creatinine, blood sugar, cholesterol, and triglycerides were within 
normal limits. There was no difference in clinical parameters 
between test groups (p>0.05). 
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Table 2: Participants' clinical condition before receiving BCSO, participants were healthy male smokers 
Parameter  Experimental groups P 
Placebo (n=9) BCSO 3x1 (n=9) BCSO 3x2 (n=12) BCSO 3x3 (n=9) Total (n=39)  
SBP 133.14±17.15 143.14±37.52 140.25±19.71 135.00±9.48 137.97±22.30 0.85 
DBP 86.57±8.34 89.29±20.77 86.37±10.47 80.57±7.32 85.72±12.50 0.86 
Hearth Rate 83.29±41.19 83.42±40.88 81.13±6.48 83.71±8.64 82.59±8.91 0.52 
Temperature  35.28±0.49 35.85±0.69 35.64±0.52 35.86±0.38 35.67±0.65 0.51 
BMI 23.57±3.95 22.71±3.30 25.00±5.75 25.71±6.68 24.24±4.95 019 
Ureum 33.57±11.08 33.54±6.57 28.59±5.79 28.74±4.96 31.11±7.53 0.21 
creatinin 1.17±0.20 1.09±0.099 1.04±0.08 1.06±0.11 1.09±0.14 0.76 
Blood glucose  131.8±915.60 145.20±53.12 166.80±46.59 131.89±24.84 144.58±40.15 0.14 
Triglyceride 172.67±77.59 150.20±76.39 164.70±60.83 188.33±151.63 168.37±93.75 0.53 
cholesterol 159.22±41.08 151.30±29.05 152.00±25.56 154.78±26.60 154.18±29.86 0.48 
Note: SBP=systolic blood pressure; DBP=diastolic blood pressure; BMI=body mass index; BCSO=black cumin seed oil; Data were given in mean+SD 
 
BCSO effects on the number of platelets, Clotting time (CT), and 
blooding time (BT) 
The impact of BCSO consumption for 30 d on platelet count, CT, and 
BT in healthy volunteers-smokers are presented in table 3. 
Average values in healthy humans are: Clotting Time =9-15 min and 
Bleeding Time=1-5 min. Based on table 3, it is known that the CT, BT, and 
platelet count values in the four test groups were within normal limits. 
The smoking habit of the participants did not affect the CT and BT values 
and the number of platelets. There was a decrease in platelet count and 
BT value in the treatment group compared to the placebo group, but it 
was not statistically significant (p>0.05). Consumption of BCSO for 30 d 
did not affect CT and BT healthy volunteer smokers in the placebo group 
with the treatment group. There was no difference in the mean CT and 
BT between treatment groups (p>0.05). Consumption of BCSO for 30 d 
by healthy volunteer smokers did not affect CT/BT. 
 
Table 3: The average value and standard deviation of clotting time, bleeding time, and number of platelet for healthy_smoking volunteers 
(HSV) who consume BCSO in the work area of PJ1BY for the period September-October 2019 
Experimental group (n) Clotting time  Bleeding time  Platelet count  
Placebo (n=9) 10.89±1.05 3.22±0.44 243.22±40.01 
BCSO 3X1 (n=9) 11.89±1.61 3.22±0.44 208.33±39.52 
BCSO 3X2 (n=12) 10.75±1.71 3.17±0.38 237.75±47.56 
BCSO 3X3 (n=9) 10.44±1.66 3.11±0.33 245.44±68.58 
Total (n=39) 10.97±1.58 3.18±0.38 236.05±50.43 
P 0.31 0.21 0.25 
Note: BCSO=black cumin seed oil; capsule of BCSO = 450 mg of BCSO without a shell; One placebo capsule = 450 mg placebo without shell; Data 
were given in mean±SD 
 
DISCUSSION 
All volunteers are men, mostly as construction workers and casual 
daily laborers, who have graduated from elementary school 
education and are in the productive age group (table 1). The clinical 
and chemical parameters for the participants are in expected value 
(table 2). The CT and BT of all test groups were within normal limits 
(table 3). Based on the data in Tables 2 and 3, it is known that the 
smoking habits of volunteers have not affected the clinical 
parameters and the CT, BT, and platelet count values. Data from this 
study are not following the results of previous studies [35,36]. 
Research had shown that acute smoking could change the platelet 
count and induce endothelial damage. The effect of smoking on the 
clotting time and bleeding time in healthy men was a shortening of 
clotting time and bleeding time in moderate and heavy smokers 
[37]. Elkhalifa's (2018) study, which examined the effect of cigarette 
smoking on the coagulation screening test and platelet counts in a 
Sundanese male adults population, that the average prothrombin 
time (PT) was significantly shorter in smokers when compared to 
non-smokers [35]. Smoking has been identified as a principal 
underlying etiology for the occurrence and progression of 
cardiovascular diseases, inflammatory disorders, and oxidative 
stress stimulation [38]. Cigarette smoking’s crucial role in disrupting 
platelet activation and aggregation, as well as other coagulation 
processing components leading to thrombotic formations, has been 
recently suggested [36]. The pathophysiological effects of cigarette 
smoking on platelet activation have been recently investigated [10, 
39]. Until now, the impact of smoking on the platelets is not all clear. 
Previous research has shown that acute smoking can alter platelet 
counts and cause endothelial damage [29]; however, in other 
studies, smoking did not induce platelet aggregation as a result of 
stimulation by effects such as adenosine diphosphate (ADP), 
epinephrine, and collagen, has been recently suggested [40]. We 
apologize that some of the factors causing the difference in Our 
results may be include differences in subject characteristics, lifestyle, 
and smoking intensity. Participants in this study were construction 
workers with a lot of physical activity and with a mild to the 
moderate smoking habit. El khalifa's research involved participants 
with moderate to severe smoking habits [35].  
Based on the data in table 3, it is known that the consumption of 
BCSO for 30 d did not affect the platelet count, CT, and BT values. 
There was no difference in the number of platelets between the 
placebo group and the treatment group (p>0.05). Based on table 3, it 
is known that the platelet count, CT, and BT values are within 
normal limits or in homeostatic conditions [41], and consumption of 
BCSO for 30 d does not change homeostasis. Based on this evidence, 
the consumption of BCSO for 30 d did not alter the homeostasis of 
healthy-smoker volunteers. The results of this study are following 
previous research data, which proves that consumption of BCSO for 
20 in healthy volunteers is safe and can be tolerated [42]. 
There are several limitations of this study, i.e. (i) we couldn’t control 
the food consumed by the participants, (ii) the number of 
participants involved was also still limited, and (iii) loose variations 
in physical activity and lifestyle of participants, so that many 
confounding factors are difficult to control. 
CONCLUSION 
Consumption of black cumin seed oil for 30 d in Healthy-smoker 
volunteers did not affect the platelet count and the value of clotting 
time and bleeding time. 
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